Cover Image
市場調查報告書

中度乾癬的開發中產品分析

Moderate Psoriasis - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 251615
出版日期 內容資訊 英文 136 Pages
訂單完成後即時交付
價格
Back to Top
中度乾癬的開發中產品分析 Moderate Psoriasis - Pipeline Review, H2 2015
出版日期: 2015年11月30日 內容資訊: 英文 136 Pages
簡介

乾癬是最常見的皮膚病的一種,特徵是皮膚發炎變紅,並包覆一層銀色皮屑的狀態。皮膚整體5∼10%包覆皮屑的狀態便被分類為「中度」。主要的症狀有皮膚發炎及產生皮屑、皮膚變厚龜裂(伴隨出血)、發癢、疼痛、灼熱感、關節腫、僵硬化等。致病危險因子有壓力及氣候變化、鏈球菌和HIV病毒的感染、皮膚表面的受傷、攝取特定藥劑(鋰等)、β- 阻斷劑(Propranolol 等)奎尼丁錠(心臟疾病用),抗瘧疾藥等。

本報告提供全球各國治療中度乾癬用的開發中產品開發情形相關分析,產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

中度乾癬概要

治療藥的開發

  • 中度乾癬開發中產品:概要
  • 中度乾癬開發中產品:比較分析

各企業開發中的中度乾癬的治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

中度乾癬的治療藥:開發中的產品一覽(各企業)

中度乾癬的治療藥的開發企業

  • Johnson & Johnson
  • Boehringer Ingelheim GmbH
  • Amgen Inc.
  • Eli Lilly and Company
  • AbGenomics International, Inc.
  • ApoPharma Inc.
  • OPKO Health, Inc.
  • Idera Pharmaceuticals, Inc.
  • Almirall, S.A.
  • Syntrix Biosystems, Inc.
  • Vascular Biogenics Ltd.
  • GlycoMar Limited
  • Avexxin AS

中度乾癬:治療藥的評估

  • 單劑治療藥的情況
  • 標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • ixekizumab(ixekizumab)
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • LAS-41008
  • IMO-3100
  • AbGn-168H
  • VB-201
  • lunacalcipol
  • guselkumab
  • Apo-805-K1
  • BI-655066
  • IMO-8400
  • MOL-4249
  • AVX-001
  • AMG-811
  • guselkumab
  • aminopterin sodium
  • AKP-11
  • cyclosporine
  • GLY-198
  • GLYK-5006

中度乾癬治療藥:開發中產品的最新趨勢

中度乾癬治療藥:暫停開發的產品

中度乾癬治療藥:中止開發的產品

中度乾癬相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全2件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7331IDB

Summary

Global Markets Direct's, 'Moderate Psoriasis - Pipeline Review, H2 2015', provides an overview of the Moderate Psoriasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Moderate Psoriasis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Moderate Psoriasis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Moderate Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Moderate Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Moderate Psoriasis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Moderate Psoriasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Moderate Psoriasis Overview
  • Therapeutics Development
    • Pipeline Products for Moderate Psoriasis - Overview
  • Moderate Psoriasis - Therapeutics under Development by Companies
  • Moderate Psoriasis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Moderate Psoriasis - Products under Development by Companies
  • Moderate Psoriasis - Companies Involved in Therapeutics Development
    • AbGenomics International, Inc.
    • ADC Therapeutics Sarl
    • Almirall, S.A.
    • AstraZeneca Plc
    • Avexxin AS
    • Boehringer Ingelheim GmbH
    • Celgene Corporation
    • Convoy Therapeutics, Inc.
    • Crescendo Biologics Limited
    • Delenex Therapeutics AG
    • Eli Lilly and Company
    • Forward Pharma A/S
    • Galectin Therapeutics, Inc.
    • GlycoMar Limited
    • Idera Pharmaceuticals, Inc.
    • Johnson & Johnson
    • Merck KGaA
    • OPKO Health, Inc.
    • Sandoz International GmbH
    • Soligenix, Inc.
    • Sun Pharma Advanced Research Company Ltd.
    • Syntrix Biosystems, Inc.
    • Valeant Pharmaceuticals International, Inc.
  • Moderate Psoriasis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (halobetasol propionate + tazarotene) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AbGn-168H - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AKP-11 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • aminopterin sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AVX-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • baricitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BI-655066 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • brodalumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CB-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CC-90005 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • COVA-322 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cyclosporine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dimethyl fumarate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dimethyl fumarate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DLX-105 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLY-2028 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GRMD-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • guselkumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMO-8400 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ixekizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lunacalcipol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-1095 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • orilotimod potassium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SGX-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tazarotene - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tildrakizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • toreforant tartrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VM-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Moderate Psoriasis - Recent Pipeline Updates
  • Moderate Psoriasis - Dormant Projects
  • Moderate Psoriasis - Discontinued Products
  • Moderate Psoriasis - Product Development Milestones
    • Featured News & Press Releases
      • Sep 11, 2014: Delenex Announces New Clinical Data
      • Mar 28, 2012: Amgen Announces Publication Of Phase II Study Results Of Brodalumab For Treatment Of Psoriasis In New England Journal Of Medicine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Moderate Psoriasis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Moderate Psoriasis - Pipeline by AbGenomics International, Inc., H2 2015
  • Moderate Psoriasis - Pipeline by ADC Therapeutics Sarl, H2 2015
  • Moderate Psoriasis - Pipeline by Almirall, S.A., H2 2015
  • Moderate Psoriasis - Pipeline by AstraZeneca Plc, H2 2015
  • Moderate Psoriasis - Pipeline by Avexxin AS, H2 2015
  • Moderate Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • Moderate Psoriasis - Pipeline by Celgene Corporation, H2 2015
  • Moderate Psoriasis - Pipeline by Convoy Therapeutics, Inc., H2 2015
  • Moderate Psoriasis - Pipeline by Crescendo Biologics Limited, H2 2015
  • Moderate Psoriasis - Pipeline by Delenex Therapeutics AG, H2 2015
  • Moderate Psoriasis - Pipeline by Eli Lilly and Company, H2 2015
  • Moderate Psoriasis - Pipeline by Forward Pharma A/S, H2 2015
  • Moderate Psoriasis - Pipeline by Galectin Therapeutics, Inc., H2 2015
  • Moderate Psoriasis - Pipeline by GlycoMar Limited, H2 2015
  • Moderate Psoriasis - Pipeline by Idera Pharmaceuticals, Inc., H2 2015
  • Moderate Psoriasis - Pipeline by Johnson & Johnson, H2 2015
  • Moderate Psoriasis - Pipeline by Merck KGaA, H2 2015
  • Moderate Psoriasis - Pipeline by OPKO Health, Inc., H2 2015
  • Moderate Psoriasis - Pipeline by Sandoz International GmbH, H2 2015
  • Moderate Psoriasis - Pipeline by Soligenix, Inc., H2 2015
  • Moderate Psoriasis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015
  • Moderate Psoriasis - Pipeline by Syntrix Biosystems, Inc., H2 2015
  • Moderate Psoriasis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Moderate Psoriasis Therapeutics - Recent Pipeline Updates, H2 2015
  • Moderate Psoriasis - Dormant Projects, H2 2015
  • Moderate Psoriasis - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Moderate Psoriasis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top